Articles published by DIAGONAL THERAPEUTICS, INC

Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
From DIAGONAL THERAPEUTICS, INC
Via GlobeNewswire
Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments
From DIAGONAL THERAPEUTICS, INC
Via GlobeNewswire
Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)
From DIAGONAL THERAPEUTICS, INC
Via GlobeNewswire
Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference
From DIAGONAL THERAPEUTICS, INC
Via GlobeNewswire
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases
From DIAGONAL THERAPEUTICS, INC
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.